文献速递肝病

苯扎贝特对熊去氧胆酸应答欠佳的原发性胆汁性胆管炎患者结局与瘙痒的影响

Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
PubMed 文献 · Am J Gastroenterol · 2017-10-10

48例熊去氧胆酸应答欠佳的原发性胆汁性胆管炎患者接受苯扎贝特(400 mg/天)联合熊去氧胆酸(13-16 mg/kg/天)治疗,中位38个月后26例(54%)碱性磷酸酶恢复正常;这些患者黄疸、瘙痒和肝脏硬度更低、年龄更高,未恢复正常者中5例(23%)出现疾病进展事件,瘙痒患者中除1例外均获部分或完全缓解。

要点

  • 苯扎贝特联合熊去氧胆酸长期治疗可使54%应答欠佳患者碱性磷酸酶恢复正常。
  • 碱性磷酸酶未恢复正常的晚期患者仍有疾病进展风险,5例(23%)出现事件。
  • 瘙痒患者中除1例外均获部分或完全缓解,停药后瘙痒复发或加重。

核心结论

  • 熊去氧胆酸联合苯扎贝特长期治疗应答良好,并与瘙痒完全或部分缓解相关;碱性磷酸酶未完全恢复正常的晚期患者仍有发生严重事件的风险,联合治疗对纤维化程度较低和胆汁淤积较轻的患者更有效。

研究设计与样本

  • 研究纳入48例(女性45例)接受熊去氧胆酸治疗且碱性磷酸酶高于正常上限1.5倍的原发性胆汁性胆管炎患者,给予苯扎贝特400 mg/天联合熊去氧胆酸13-16 mg/kg/天,评估临床特征、肝脏生化、预后及瘙痒(视觉模拟量表43例和5-D描述性瘙痒量表)。

主要发现

  • 中位38个月后26例(54%)碱性磷酸酶恢复正常,这些患者黄疸、瘙痒和肝脏硬度低于碱性磷酸酶仍升高者,年龄高于后者。
  • 碱性磷酸酶未恢复正常的患者生化改善较不明显,其中5例(23%)发生疾病进展事件:1例死亡、3例接受移植、1例发生肝细胞癌。
  • 瘙痒患者中除1例外均报告部分或完全瘙痒缓解,停用苯扎贝特后观察到瘙痒复发或加重。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Adding fibrates improves liver biochemistries in patients with primary biliary cholangitis (PBC) and suboptimal response to ursodeoxycholic acid (UDCA). As there are no consistent data regarding the course and outcome, we have assessed the effects of the combined treatment with UDCA and bezafibrate on a long-term basis. METHODS: A total of 48 patients (45 female) with PBC treated with UDCA and alkaline phosphatase (ALP) above 1.5 times upper normal levels (× UNL) were treated with bezafibrate (400 mg/day) plus UDCA (13-16 mg/kg/day). Changes in clinical features, liver biochemistries, and prognosis after therapy were assessed, as well as pruritus, using a visual analog scale (43 patients) and the 5-D descriptive pruritus scale. RESULTS: After a median of 38 months, 26 patients (54%) had normalized ALP. In these patients, jaundice, pruritus, and liver stiffness was lower, and age was higher than in patients who remained with elevated ALP. Biochemical improvement was less prominent in patients without ALP normalization. Five of these patients (23%) developed events of disease progression: 1 died, 3 were transplanted, and 1 developed hepatocellular carcinoma. Partial or complete itching relief was reported in all but one case with pruritus. Itching recurrence or worsening was observed after bezafibrate discontinuation. CONCLUSIONS: The long-term treatment with UDCA and bezafibrate results in excellent response, and is associated with a complete or partial itching relief. Incomplete ALP normalization was observed in patients with advanced disease who remained at risk for developing severe events. The combined treatment is mainly effective in patients with lower fibrosis and severity of cholestasis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Reig A, Sesé P, Parés A, et al. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Am J Gastroenterol. 2017. PMID: 29016567. doi:10.1038/ajg.2017.287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。